The University of Colorado Anschutz Gates Institute received FDA Investigational New Drug (IND) clearance for a novel CAR T-cell therapy designed and built on campus, marking a first-in-the-U.S. milestone for a fully institution-developed CAR T program. The clearance supports initiation of clinical testing, highlighting an emerging model where academic centers pair specialized manufacturing capabilities with regulatory-grade quality systems rather than relying solely on external partners. For the CAR T ecosystem, this development increases attention on in-house process control and institutional scale-up readiness, particularly as CAR T manufacturing capacity becomes a recurring constraint. The IND clearance also signals confidence in the therapy’s development package and manufacturing approach, which can influence how other universities and translational centers plan future cell-therapy programs.